“Bimekizumab Efficacy and Safety Over 48 Weeks in US and Canadian Patients With Psoriasis Who Had a Treatment Interruption After 3 Years of Treatment: Results from BE RADIANT”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s431, https://doi.org/10.25251/skin.8.supp.431.